| Drug ID: | Drug114 |
|---|
| Drug Name: | XELJANZ |
|---|
| CID: | 10174505 |
|---|
| DrugBank ID: | NULL |
|---|
| Modality: | Small Molecule |
|---|
| Groups: | NULL |
|---|
| US Approved: | NULL |
|---|
| Other Approved: | NULL |
|---|
| Identifier: |
NCT00152841
|
|---|
| Molecular Formula: | C22H28N6O8 |
|---|
| Molecular Weight: | 504.5 g/mol |
|---|
| Isomeric SMILES: | C[C@@H]1CCN(C[C@@H]1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
|---|
| Synonyms: | Tofacitinib citrate; 540737-29-9; Xeljanz; CP-690550 citrate; Xeljanz Xr; Tasocitinib monocitrate; UNII-O1FF4DIV0D; O1FF4DIV0D; CP-690550-10; CHEBI:71197 |
|---|
| Phase 0: | 0 |
|---|
| Phase 1: | 0 |
|---|
| Phase 2: | 0 |
|---|
| Phase 3: | 0 |
|---|
| Phase 4: | 0 |
|---|
| Description: | NULL |
|---|
-
-
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
| No data available |
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
| NCT05104723 |
Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications |
PHASE1|PHASE2 |
ENROLLING_BY_INVITATION |
National Institute of Allergy and Infectious Diseases (NIAID) |
Chronic Granulomatous Disease|Inflammatory Gastro… |
DRUG: XELJANZ (tofacitinib) |
Details |
| NCT03643211 |
Xeljanz Special Investigation for Long-term Use in UC Patients |
None |
COMPLETED |
Pfizer |
Ulcerative Colitis |
None |
Details |
| NCT04071405 |
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients |
None |
COMPLETED |
Pfizer |
Ulcerative Colitis |
OTHER: Non-intervention |
Details |
| NCT04925973 |
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management |
PHASE2 |
ACTIVE_NOT_RECRUITING |
McMaster University |
Ulcerative Colitis Acute |
DRUG: Tofacitinib 10 MG [Xeljanz] |
Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
| No data available |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
| S07 |
Blockade of cytokine |
Cytokine signalling |
apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab |
Various T-cell subsets, their differentiation pathways and … |
Details |
PMID: 37393666
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: The etiopathogenesis of accompanying inflammatory phenomena and consequences of immunomodulation constitute a challenging and innovative …
